

## Article

# Neuroimmune alterations in autism: a translational analysis focusing on the animal model of autism induced by prenatal exposure to valproic acid

Deckmann, Iohann, Schwingel, Gustavo Brum, Fontes-Dutra, Mellanie, Bambini-Junior, Victorio and Gottfried, Carmem

Available at <http://clock.uclan.ac.uk/24033/>

*Deckmann, Iohann, Schwingel, Gustavo Brum, Fontes-Dutra, Mellanie, Bambini-Junior, Victorio ORCID: 0000-0002-8590-6770 and Gottfried, Carmem (2018) Neuroimmune alterations in autism: a translational analysis focusing on the animal model of autism induced by prenatal exposure to valproic acid. Neuroimmunomodulation . ISSN 1021-7401*

It is advisable to refer to the publisher's version if you intend to cite from the work.  
<http://dx.doi.org/10.1159/000492113>

For more information about UCLan's research in this area go to  
<http://www.uclan.ac.uk/researchgroups/> and search for <name of research Group>.

For information about Research generally at UCLan please go to  
<http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the [policies](#) page.

**Neuroimmune alterations in autism: a translational analysis focusing on  
the animal model of autism induced by prenatal exposure to valproic acid**

Iohanna Deckmann<sup>1,2,3</sup>, Gustavo Brum Schwingel<sup>1,2,3</sup>, Mellanie Fontes-  
Dutra<sup>1,2,3</sup>, Victorio Bambini-Junior<sup>1,3,4</sup> and Carmem Gottfried<sup>1,2,3\*</sup>

1 Translational Research Group in Autism Spectrum Disorders-GETTEA,  
Universidade Federal do Rio Grande do Sul -UFRGS, 90035-003 Porto Alegre,  
RS, Brazil.

2 Neuroglial Plasticity Group, Department of Biochemistry, Universidade  
Federal do Rio Grande do Sul -UFRGS, 90035-003 Porto Alegre, RS, Brazil.

3 National Institute of Science and Technology on Neuroimmunomodulation-  
INCT-NIM.

4 School of Pharmacology and Biomedical Sciences, University of Central  
Lancashire, PR1 2HE, Preston, UK

\*CORRESPONDING AUTHOR:

CG (cgottfried@ufrgs.br)

Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do  
Sul, Ramiro Barcelos, 2600 – 21111. CEP: 90035-003. Porto Alegre-RS, Brazil.

## **ABSTRACT (250 words)**

Autism Spectrum Disorder (ASD) is a highly prevalent developmental disorder characterized by deficits in communication and social interaction and in stereotyped or repetitive behaviors. Besides the classical behavioral dyad, several comorbidities are frequently present in patients with ASD, such as anxiety, epilepsy, sleep disturbances and gastrointestinal tract dysfunctions. Although the etiology of ASD remains unclear, there is supporting evidence for the involvement of both genetic and environmental factors. Valproic acid (VPA) is an anticonvulsant and mood stabilizer that, when used during the gestational period, increases the risk of ASD in the offspring. The animal model of autism by prenatal exposure to VPA shows construct and face validity, since several changes seen in subjects with autism are also observed in the VPA animal model. Neuroimmune alterations are common both in autistic individuals and in animal models of autism. In addition, exposure to pathogens during the pregnancy is a known risk factor for ASD, and maternal immune activation can lead to autistic-like features in animals. Thus, immunological alterations in pregnancy could affect the developing embryo, since immune molecules can pass through the placental barrier. Here, we summarize important alterations in inflammatory markers, such cytokines and chemokines in patients with ASD and in the VPA animal model.

**Keywords** (3–9 key words): ASD, neuroimmune, cytokine, animal model, valproic acid

## 1 INTRODUCTION

2        Since the first descriptions, in the early 1940's by Leo Kanner and Hans  
3 Asperger, new data has been shared to the scientific community about Autism  
4 Spectrum Disorder (ASD) [1]. Currently, ASD is diagnosed by changes in two  
5 behavioral domains: a) communication and social interaction impairments in  
6 multiple contexts, including deficits in social reciprocity, non-verbal  
7 communication used for social interaction and in skills to initiate, maintain and  
8 understand relationships; and b) Repetitive behaviors, restricted and stereotyped  
9 activities [2].

10        There is no clinical marker or quantitative examination in peripheral tissues  
11 that can be used for an early diagnosis of this disorder [3]. Even though there are  
12 many well accepted surveys for behavioral diagnosis, ASD is a highly complex  
13 and heterogeneous disorder, presenting distinct manifestations, in which two  
14 individuals hardly share the same set of symptoms [4,5]. The large heterogeneity  
15 of the symptoms could potentially be explained by individual differences, for  
16 example in the immune system. Alterations in cytokines levels are common in  
17 autistic individuals, with a frequent observation of elevated levels of pro  
18 inflammatory cytokines [6,7].

19        Genome-wide association studies (GWAS) have already described  
20 interesting relations between immune system disruptions and neurological  
21 disorders like autism and schizophrenia [8]. Specifically in ASD, an interesting  
22 example is the dysregulated genes reported, as IL-1 $\beta$  and IL-12, both involved in  
23 cytokine-cytokine receptor interaction [9]. One study relating ASD and  
24 neuroimmune genetic disruption shows an alteration on glutamate receptor

metabotropic 5 (GRM5) single nucleotide polymorphisms (SNPs) [10], which is not exactly a neuroimmunological alteration, but this gene is highly expressed in many neuronal regions implicated in ASD, besides acting on synaptic plasticity, modulating innate immunity and microglia activation. When occurs a GRM5-positive allosteric modulation, several negative behaviors described in ASD are rescued, including stereotypies [10]. Taken together, the evidences showing genes interaction and ASD diagnosis demonstrate important genetic contribution in neuroimmunological imbalance in ASD. However, despite the data cited above, no gene was identified as an important actor in triggering this disorder.

According to the most recent epidemiological survey conducted in United States, the current incidence of ASD is 1:68 [11]. Although the etiology of ASD remains unknown, it is hypothesized that the onset of this disorder depends on the interplay between genetic and environmental factors. Epidemiological observations suggest that exposure to teratogens - especially in the first trimester of pregnancy - could be closely related to ASD development. An important example is the prenatal exposure to valproic acid (VPA) [12,13].

### **Valproic acid (VPA) and VPA animal model**

The compound VPA is a drug widely used as an anticonvulsant and mood stabilizer in the treatment of epilepsy and bipolar disorder [13,14]. Although VPA is well tolerated and safe in adults, there is evidence of its teratogenicity [14]. Clinical studies over the years have shown that intrauterine exposure to VPA is associated with birth defects, cognitive impairments, and increased risk of autism [13]. In recent years, animal studies have investigated the anatomical, behavioral,

1 molecular, immunological and physiological outcomes related to exposure to  
2 VPA [13].

3 Epidemiological observations demonstrate a strong correlation between  
4 prenatal exposure to VPA and ASD [15–18]. Based on these observations, an  
5 animal model for study of autism prenatally induced by VPA was established [19–  
6 21]. Behavioral studies show that exposure to VPA in rats and mice leads to  
7 several autistic-like behaviors in male offspring, including social behavior deficits,  
8 increased repetitive behaviors, and communication deficits similar to those found  
9 in ASD subjects [19–23], pointing out the animal model's translationality, as the  
10 diagnosis of ASD is given through behavioral evaluation.

11 Since current diagnostic criteria for ASD are exclusively clinical and  
12 resulted from behavioral analyses, the study of ASD in humans prior to the onset  
13 of symptoms becomes a very challenging task. Animal models provide the  
14 opportunity for analyzing the developmental changes that can trigger ASD-like  
15 features [24,25]. They provide the possibility to study and manipulate biological  
16 pathways for understanding and even preventing or reversing the appearance of  
17 the morphological, functional and behavioral alterations found in ASD. In addition,  
18 studies with animals can reveal some new important factors involved in the  
19 etiology of this disorder.

## 20 **Histone-deacetylases inhibitors (HDACi) and neuroimmune alterations**

21 Autism and many other psychiatric disorders, like schizophrenia, bipolar  
22 disorder and major depression present not only susceptibility to environmental  
23 risk factors, but also a high genetic influence [26,27]. In the last years, there is

growing evidence indicating that epigenetic alterations may have an important role in several psychiatric disorders.

Epigenetic regulation includes long-term changes, as DNA methylation, and short-term changes, as modifications in histone proteins associated with DNA [28]. Histones are small basic proteins that act as spools around which DNA winds, regulating the packaging of DNA and allowing or inhibiting gene expression. When the histone is acetylated by histone acetyltransferases (HATs), this local alteration leads to chromatin decondensation, promoting gene expression by the activation of the transcription machinery. On the other hand, histone deacetylation - mediated by histone deacetylases (HDACs), results in inhibition of transcription promoting a controlled gene expression [28,29].

Substantial epigenetic alterations were found in the regulatory regions of many candidate genes for ASD, such as GABAergic genes, GAD67, Reelin, Oxytocin receptor, BDNF, showing that the epigenetic component in ASD has been widely studied [26]. The histone post-translational modifications, as acetylation and methylation, play a key role in the gene expression regulation [30]. These characteristics are crucial for important biological processes like the action of immune system, in which HDACs modulate gene expression of toll-like receptors and interferon signaling pathways [31].

The HDAC inhibitors drugs play an important role in immune context. Studies showed an increased transcription of the major histocompatibility complex (MHC) class II, located in the tumor cell surface in mouse and humans [32], indicating an interesting effect on several immune cells. It leads to less viability of T CD4 cells and decreases the production of pro-inflammatory

cytokines, making the T CD8 cells increase the secretion of pro-inflammatory cytokines, modulating the activity of natural killer (NK), as well in cells and Treg cells [33].

Hence, several drugs used as antidepressants and mood stabilizer are characterized as HDAC inhibitors class. Valproate, a well-known HDAC inhibitor drug, induces important delays in the neuronal maturation [34], already described in ASD [35]. Moreover, VPA prenatal exposure alters the postnatal histone 3 (H3) acetylation levels in cerebellum [36], stimulates glial cell proliferation in the developing rat brain [37] and also induces changes in acetylation levels in astrocytes of hippocampus and cortex in cell culture, more than other antidepressants and mood stabilizer [38]. These unique effects of VPA, especially in comparison to similar HDAC inhibitor drugs, indicate that the VPA molecule might have exclusive properties which are still unclear, although some evidence indicates a possible VPA binding in the catalytic center of HDACs [39]. Those epigenetics alterations occur before the well described neuroimmune alterations, and, thus, epigenetics mechanisms may be involved in the immune disturbance [36]. These data highlight the role of the valproic acid and HDAC inhibitors as epigenetic modulators that could be underpinning the immunological alteration, as well as the neurological outcomes, in psychiatric disorders.

## **The intimate relationship between central nervous system and immune system**

For a long time, immune and central nervous systems were considered compartments that operate separately and independently. However, recent studies demonstrate an active communication between these two systems,



1 modulating bi-directly each other with neurotransmitters and neuromodulators in  
2 periphery. In addition, in a landmark study, lymphatic vessels were discovered in  
3 central nervous system, putting in check the current view of the brain as an  
4 “immune privileged site” and raising new possibilities for the crosstalk between  
5 brain and immune system [40]. Anatomically the central nervous system (CNS)  
6 is bathed by the cerebrospinal fluid (CSF) and surrounded by the meninges,  
7 which contain lymphatic and blood vessels [41]. The brain parenchyma is  
8 separated from the circulating blood by a blood-brain barrier (BBB), which  
9 prevents the entry of pathogens, circulating immune cells, and other substances  
10 from the blood.

11       The BBB is defined as a semipermeable membrane that separates the  
12 circulating blood from the brain and extracellular fluid in the central nervous  
13 system [42]. CNS blood vessels interact with different peripheral and brain-  
14 resident immune cell populations, as perivascular macrophages and microglial  
15 cells, respectively. The BBB is formed by the concerted action of endothelial and  
16 glial cells. During development, at embryonic day 10 (E10), initial clues for  
17 angiogenesis lead to the early properties of BBB in CNS by activation of the  
18 Wnt/b-Catenin canonical pathway [43–45]. There is no consensus about the  
19 exact time when the BBB is fully formed [46]. Nevertheless, at E15, pericytes,  
20 which have crucial roles in BBB formation and maintenance, begin to interact  
21 intimately with endothelial cells (EC) in the capillary walls [47]. In postnatal life,  
22 endothelial cells from brain capillaries are covered up by mature pericytes,  
23 sharing their basement membrane with endothelial cells [48]. Moreover, the  
24 astrocytes project cellular terminations called “end feet” toward the capillaries,  
25 providing the outer layer of the BBB. Pericytes and astrocytes also secrete

1 proteins involved in extracellular matrix formation and deposition of the basement  
2 membrane [48,49].

3       The presence of this limiting barrier allows the CNS to control and fine tune  
4 the flow of a variety of molecules from periphery, regulating its permeability to  
5 seek homeostasis. In CNS physiology, there are extensive vessels where  
6 monocytes, granulocytes and dendritic cells circulate [50]. In addition, the brain  
7 parenchyma is populated with microglia, resident-cells from the immune lineage  
8 that play crucial roles in brain surveillance and response against multiple types  
9 of damage. Studies with rodents showed that, during neurodevelopment, specific  
10 monocytes emerge at E7 and infiltrate the CNS at E9.5 as pre-macrophages,  
11 expressing the chemotactic factor CX3C chemokine-receptor 1 (CX3CR1) [50].  
12 The presence of cytokines as interleukin-1 beta (IL-1 $\beta$ ) and tumor growth factor  
13 beta (TGF- $\beta$ ) allows the differentiation of pre-macrophages in early microglia at  
14 E14.5, which then generate mature microglia at P14. In fact, TGF- $\beta$  seems to be  
15 crucial for microglial specification in CNS [51,52].

16       Microglial cells are capable to interact with almost all cell types in the CNS  
17 modulating cell maturation during development and promoting tissue repair and  
18 homeostasis. Moreover, in postnatal life, microglia play crucial roles in sensing  
19 perturbations in encephalic environment, actively responding to even minor  
20 pathological changes in CNS [53,54] by altering their shape and gene expression  
21 profile. The term “microglial activation” has been considered as a shift from a  
22 “resting” stage to an “activated” state when disturbance of tissue homeostasis is  
23 detected or upon experimental stimulation. However, this term implies the  
24 understanding of an “inactivated” phenotype when brain tissue is not facing any

1 changes in homeostasis. In fact, microglial cells are never inactive, showing  
2 highly dynamic surveillance functions in CNS [50,55,56]. Many authors are  
3 suggesting to rename this surveillance state of microglial cells to “surveying  
4 microglia”, instead of “resting microglia” [50]. These cells can shift from their  
5 “surveying” or “resting” state to “activated” or “alerted” state when facing changes  
6 in CNS homeostasis, as infections recognized by toll-like receptors [57], cell  
7 damage or trauma. Recent studies have demonstrated that the  
8 lipopolysaccharide (LPS) exposure downregulates the transcriptional factor Sal-  
9 like protein 1 (SALL1) and promotes several alterations in microglial identity, with  
10 a concomitant upregulation of genes associated to other resident macrophages,  
11 indicating that SALL1 might be important for maintenance of microglial identity in  
12 response to immune challenge [50,58]. Once activated, microglial cells can  
13 commit to different phenotypes called “reactive”, having a large functional and  
14 molecular diversity. These changes in microglia profile are correlated with the  
15 type of challenge faced by the CNS. They can shift to a pro-inflammatory state  
16 also called “M1 phenotype” [59] presenting highly phagocytic and neurotoxic  
17 activities and releasing pro-inflammatory chemokines and cytokines in response  
18 to an immune challenge, such as a microorganism invasion [60] or the presence  
19 of pro inflammatory signals [61–63]. Once the immune stimulator is controlled,  
20 microglial cells are able to shift to a more neuroprotective profile called “M2  
21 phenotype” which involves anti-inflammatory responses [59,64]. Nonetheless,  
22 the activated pro-inflammatory profile can progress in pathological conditions.  
23 Although the immune challenge and the brain environment are responsible for  
24 the early microglial responses, signals from CNS resident and infiltrating immune  
25 cells can shape reactive profiles of microglial cells and play important roles in

1 many brain diseases [65–69]. All these stimuli could direct microglia's fate to  
2 alternative states, including microglial cell death, but there's still scarce  
3 information about the course of microglial activation, their reversibility to the  
4 surveying state [70] or the preservation of molecular memory of previous stimuli.  
5 Moreover, cells that infiltrate from the blood and differentiated into microglia could  
6 also return to the periphery [65,71].

7       There is a low basal entry of immune cells from blood periphery into the  
8 CNS in normal conditions. Studies have shown that, although microglial cells play  
9 major roles in brain surveillance, the perivascular macrophages represent a  
10 crucial immune regulator and sensor of perturbations in CNS and periphery.  
11 These cells are derived from bone marrow and are intimately associated with the  
12 bloodstream since they reside between endothelial cells and astrocyte's end feet  
13 [72–74]. This privileged location of perivascular macrophages allow them to  
14 simultaneously monitor the blood and the brain interstitial fluid, providing a fine  
15 control of brain homeostasis and BBB integrity [72,75]. Although macrophages  
16 display different locations, they can perform specific roles in these  
17 microenvironments. In addition to perivascular space, macrophages can be  
18 located within choroid plexus and meningeal space. In choroid plexus, which is  
19 considered the major site of CNS immune surveillance, there are tissue-resident  
20 macrophages called epiplexus cells disposed alongside the fourth ventricle with  
21 dendritic cells (DC), monocytes and mast cells [76,77]. Referred by many authors  
22 as the “immune regulatory gate”, the choroid plexus is capable to induce specific  
23 immune responses and allows cell migration between blood and CSF [78,79].  
24 The meningeal macrophages are positioned in the subdural meninges and act as  
25 sentinel cells for damage and infection in brain tissue, surveying the

cerebrospinal fluid (CSF) and the extracellular lumen of meningeal blood vessels [80,81]. Thus, macrophages play critical roles in CNS surveillance, homeostasis and disease. Nonetheless, there is a variety of other immune cell types in the brain environment. In physiological condition, studies have observed the presence of monocytes in meningeal spaces, although more evidence is still needed [82]. Granulocytes (neutrophils, mast cells, eosinophils, and basophils) can be found in meningeal spaces with mast cells also present in brain parenchyma [72,83]. These cells are highly phagocytic and play important roles in response to brain infections and tissue damage [72,84,85]. Dendritic cells (DC), the main antigen-presenting cells in periphery, can also be found in CNS. They are located in the choroid plexus, meningeal space, and are specially abundant in lymphatic vessels in meninges [86–88]. The presence around these vessels suggests important roles for DC in inflammatory diseases and brain infections [40].

During inflammatory condition, there is extensive infiltration of immune cells in the CNS. The barriers that regulate cellular entry are the blood-brain barrier (BBB) within the CNS parenchyma, and the blood-cerebrospinal fluid (blood-CSF) barrier within the choroid plexus” [89]. When brain homeostasis is compromised, immune cells can infiltrate from the periphery to the brain parenchyma due to the elevation in BBB permeability. This is generally observed and investigated in the context of a pathological CNS inflammatory response [90–92]. Under pathological conditions, microglia activation can lead to BBB disruption, allowing a substantial cellular infiltrate and amplifying the inflammatory response [93,94]. One of the key mediators in these processes is the release of cytokines and chemokines by periphery and brain-resident immune cells. This

novel view of the immune system as an active player in brain function is modifying our current view of neuropsychiatric disorders. Immune alterations are now seen as central for the pathophysiology of many brain diseases and further understanding of this neuroimmune axis can result in new therapies and diagnostic tools.

## **Neuroimmune alterations in ASD: from patients to the VPA animal model**

In the last decade, the immune system has caught the attention of neuroscientists for the interplay between neurons and immune mediators, not only in disease, but also in the homeostasis of the brain. In the past, the central nervous system was called “an immune-privileged region”, once the blood brain barrier controls the cross talking between brain and the periphery. However, recent findings demonstrated that this privilege is not related to the absence of immune modulation in brain activity and homeostasis, but a time-dependent specific modulation in many regions during brain development [95]. Immune cells and immune molecules, such as cytokines and chemokines, can modulate cognitive, emotional and behavioral processes, triggering different responses in neuronal and glial cells [96]. Cytokines are small signaling-molecules acting as mediators of communication between immune cells. Their roles include stimulation and regulation of cell development, maturation and response against immune challenges [97,98]. Chemokines can be characterized as a vast group of 8-10 kDa molecules from the super family of cytokines that induce chemotaxis of immune cells. Once bound in their receptor, the complex chemokine-receptor can activate signaling cascades that induce immune cell trafficking to the target area. Also, this complex plays important roles as molecular signal in crosstalk

1 among neuronal and glial cells and immune resident cells in nervous system, as  
2 microglia [99,100]. Since chemokines are capable to target different types of  
3 receptor, they can modulate different cell processes, including cell adhesion,  
4 proliferation, phagocytosis, apoptosis, angiogenesis, cytokine secretion and T  
5 cell activation [101].

6 Lymphocytes are cells capable of recognizing any foreign antigens  
7 displayed by antigen-presenting cells, constituting the main cells of adaptive  
8 immunity [102]. Lymphocytes respond by proliferating and differentiating in  
9 effector cells, whose function is the elimination of the pathogen and creation of  
10 an immunological memory [103]. When naïve CD4<sup>+</sup> T cells encounter specific  
11 antigens, they can differentiate into a range of effector subgroups. Several  
12 transcription factors are individually required for T-cell differentiation, generating  
13 a specific lineage that express characteristic cytokines. That is, once specific  
14 transcription factors are activated, they promote differentiation of naïve T cells,  
15 which differentiate into specific immunological responses: Th1, Th2 and Th17. In  
16 the presence of IFN- $\gamma$  and IL-12, Signal transducer and activator of transcription  
17 (STAT) 1 and STAT4 signal for the expression of the transcription factor T box  
18 expressed in T cells (T-bet) and promotes response Th1. On the other hand, Th2  
19 cell commitment occurs when IL-4 and STAT6 increase expression of GATA-  
20 binding protein (GATA3) transcription factor. The presence of TGF- $\beta$  associated  
21 with IL-6 signaling via STAT3 generating the expression of retinoid-related  
22 orphan receptor (ROR $\gamma$ t) transcription factor, results in the differentiation of Th17  
23 cells. Also, TGF- $\beta$ , with IL-2 signaling via STAT5 is known to generate, at least  
24 in vitro, inducible Treg cells, which express Foxp3 transcription factor (See Figure  
25 1) [104].

The modulation of cytokine levels can alter significantly the brain physiology and behavior. Recent studies highlight a link between immune dysfunction and behavioral impairments [105]. For example, the relation between IL-6 and several altered behaviors has already been established in the literature [106–108]. Signs of neuroinflammation and altered inflammatory response are seen in ASD subjects throughout life [109]. Therefore, some authors hypothesize that the neuroimmune disturbances could be causal for ASD [110]. Below, we will detail the main neuroimmunological findings (summarized in Tables 1 and 2) in ASD subjects and in VPA animal model of autism:

#### *IL-1 $\beta$*

IL-1 $\beta$  is a cytokine produced by fibroblasts, monocytes, tissue macrophages, dendritic cells (DCs), B lymphocytes, epithelial cells, and natural killer (NK) cells [111] that promotes inflammation by indirectly stimulating lymphocyte function and activating macrophages [112,113]. IL-1 $\beta$  has the ability to increase the expression of adhesion molecules such as VCAM-1 and ICAM-1, supporting the infiltration of inflammatory cells from the circulation into the tissue and resulting in chronic IL-1-induced inflammation [112,113]. IL-1 $\beta$  stimulates expression of inflammatory mediators and induces T-helper type 17 (Th17) response. Furthermore it can also play important roles as a mediator of the anti-inflammatory response [112,113].

Both elevation and reduction in IL-1 $\beta$  levels have already been reported in ASD subjects. Increased levels of IL-1 $\beta$  were found in plasma [114,115], serum [116,117], and peripheral blood mononuclear cells (PBMCs) [118–120] whereas decreased levels were described in neonatal dried blood samples (n-DBSS)



[121]. In VPA animal model, IL-1 $\beta$  was increased in hippocampus [122,123], in LPS-exposed hippocampus [109] and in whole brain homogenate [124]. Increased levels of this cytokine are associated with increased stereotypy [120], one of the main characteristics of ASD.

#### *IL-2*

Interleukin-2 has an important role in controlling the survival of immature and mature T cells [125] and is mainly secreted by CD8+ and CD4+ T cells after recognition of the antigen and co-stimulators [111]. IL-2 is the most important cytokine for promoting the clonal expansion of antigen-activated T cells [126]. The only report in ASD is a reduction of IL-2 levels in neonatal dried blood samples (n-DBSS) [121].

#### *IL-4*

IL-4 is the main cytokine of Th2 response and is primarily produced by T cells and mast cells. IL-4 promotes proliferation of B cells and cytotoxic T cells and stimulates IgG and IgE production [97], besides stimulating leukocytes recruitment and promoting the expression of adhesion molecules [127]. Increased levels of this cytokine were associated with greater impairments in non-verbal communication [120]. In ASD subjects, reduced level of IL-4 in n-DBSS [121] and elevated levels in amniotic fluid [128] have been reported.

#### *IL-5*

IL-5 is a cytokine produced by T cells that acts as an activator of eosinophils [129]. IL-5 promotes eosinophil proliferation and maturation,

stimulating IgA and IgM production [97]. In ASD patients, a decrease in IL-5 in n-DBSS [121] and an increase in plasma samples [115] were described.

### *IL-6*

The main source of IL-6 are T-helper cells, macrophages and fibroblasts. IL-6 targets activated B-cells and plasma cells, promoting differentiation into plasma cells and IgG production [97]. IL-6 is also involved in induction of Th17 response and has a dual profile pro- and anti-inflammatory [112,113]. Studies have demonstrated essential involvement of IL-6 in triggering core symptoms related to pro-inflammatory response in autistic model of maternal immune activation (MIA) [130].

Increased levels of IL-6 are associated with increased stereotypy in ASD [120], impaired cognitive abilities, abnormal anxiety and decreased social interactions [107]. Here, we review the main findings about IL-6 levels in ASD: IL-6 is elevated in brain tissue (cerebellum, frontal cortex and anterior cingulate gyrus) [7,131,132], and in serum and PBMC [116–120], while it is reduced in plasma and n-DBSS [114,121]. In the VPA animal model of autism, higher levels of IL-6 were reported in hippocampus [123], hippocampus and spleen after LPS challenge [109] and whole brain homogenate [124].

### *IL-8*

Interleukin-8 is a chemoattractant cytokine produced mainly by macrophages that specifically targets neutrophils, promoting their activation [133]. So, its major functions result from its chemotactic and pro-inflammatory activities [97]. Elevated levels of this cytokine were associated with increased

hyperactivity, stereotypy, and lethargy [120]. Higher levels of IL-8 was described in frontal cortex [132], plasma [115], cerebrospinal fluid (CSF) [134], PBMCs [120] and n-DBSS [121] of ASD subjects.

#### *IL-10*

This cytokine can be produced by several cellular types including DCs, macrophages, mast cells, NK cells, eosinophils, neutrophils and B cells [135], and is able to regulate growth and/or differentiation of B cells, NK cells, cytotoxic and helper T cells, mast cells, granulocytes, dendritic cells, keratinocytes, and endothelial cells, exerting a primarily anti-inflammatory activity [97,135]. IL-10 is important to fine tune the immune response against invading pathogens, maintaining the homeostatic state [135]. In ASD patients, increased levels to IL-10 were found in anterior cingulated gyrus and amniotic fluid [128,134], while IL-10 levels is decreased in PBMCs [96].

#### *IL-12*

IL-12 is produced by T cell and acts in naïve T-cells and NK cells, activating them [97], and inducing IFN $\gamma$  production, which is critical for the induction of Th1 cells [136]. Plasma, PBMCs and serum of ASD subjects show higher levels of IL-12 [115,117,120] whereas n-DBSS show lower IL-12 levels [121]. Increased IL-12 levels were associated with increased stereotypy and lethargy in ASD patients [120].

#### *IL-13*

1 Similarly to IL-4, IL-13 is involved in type-2 immunity and is produced by  
2 T-cells. However, basophils, eosinophils and NK cells can also produce IL-13  
3 [137]. The only report in autistic patients shows increased plasma levels of IL-13  
4 [115].

#### 5 *IL-17*

6 Interleukin-17 has an important role in immunity against intra and  
7 extracellular pathogens [138]. IL-17-producing cells including natural killer T cells  
8 and innate lymphoid cells play crucial roles in inflammation-associated diseases,  
9 such as infection, autoimmunity and tumors [139]. Also was described the effector  
10 role of IL-17a in onset of offspring behavioral abnormalities of mothers MIA-  
11 induced, showing the important crosstalk between the neuroinflammatory state  
12 and behavioral manifestations [140]. Increase levels of IL-17 have been reported  
13 in plasma and serum [115,141] of patients with ASD.

#### 14 *IL-23*

15 Considered a pro-inflammatory cytokine essential for the differentiation of  
16 Th17 lymphocytes [142], IL-23 is produced by macrophages, dendritic cells,  
17 keratinocytes and other antigen-presenting cells after recognition of  
18 microorganisms [143]. IL-23 is critically involved in autoimmune diseases  
19 responses [144]. In autistic patients, elevated IL-23 levels in serum samples were  
20 reported [117].

#### 21 *TNF- $\alpha$*

1           The tumor necrosis factor alpha (TNF $\alpha$ ) is an endotoxin-induced serum  
2 factor promoting phagocyte cell activation [97], whose main targets and  
3 producers are macrophages. TNF $\alpha$  is in higher levels both in patients (frontal  
4 cortex [132], PBMC [96,118,119,145], serum [117] and amniotic fluid [128]) and  
5 in the VPA animal model of autism (hippocampus and spleen responding to LPS  
6 [109] and whole brain tissue [124]).

#### 7 *IFN- $\gamma$*

8           Interferon- $\gamma$  (IFN- $\gamma$ ) plays an important role in host defense against  
9 intracellular pathogens. It is produced by NK T cells, CD8+ T cells, and T-helper  
10 1 (Th1) CD4+ T cells and its functions include supporting Th1 differentiation [146],  
11 and macrophage activation and increasing neutrophil and monocyte function [97].  
12 Patients with ASD have increased levels of IFN- $\gamma$  in frontal cortex [132], plasma  
13 [147], CSF [134] and PBMC [96] and reduced levels in n-DBSS [121].

#### 14 *TGF $\beta$ 1*

15           TGF- $\beta$  is primarily secreted by T cells and B cells, and acts in activated T  
16 and B cells. The major function of this cytokine is to inhibit hematopoiesis and T  
17 and B cell proliferation [97]. Higher levels to TGF $\beta$ 1 were reported in anterior  
18 cingulated gyrus and CSF [134] of ASD subjects.

#### 19 *MCP-1*

20           Monocyte Chemoattractant Protein-1 (MCP-1) or C-C chemokine ligand 2  
21 (CCL2) signals to cells that contain the specific CCR2 receptor, stimulating their  
22 migration to sites where CCL2 is produced and facilitating the amplification of

neuroinflammation [148]. Higher levels of MCP-1 were observed in plasma [149], CSF [134] and amniotic fluid [128] of autistic subjects. Increased levels in plasma were associated with greater impairments in visual reception, fine motor skills and expressive language [149].

#### *GM-CSF*

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is produced by T cells, macrophages and fibroblasts and targets stem cells. Its major function is to stimulate production of granulocyte, monocyte and eosinophils [97]. Diminished levels of GM-CSF were described in n-DBSS of ASD pediatric subjects [121].

#### *G-CSF*

The main source of granulocyte colony-stimulating factor (G-CSF) are fibroblasts and endothelial cells and its targets are stem cells in the bone marrow. G-CSF has a hematopoietic function and stimulates granulocyte production [97]. Higher levels of this cytokine were described in plasma of autistic patients [114].

#### *EGF*

Epidermal growth factor (EGF) is a small chemoattractant peptide produced by activated T cells that is involved with wound healing by attracting fibroblasts and epithelial cells [114]. Higher levels of this chemokine were reported in plasma samples from autistic patients [114].

#### *RANTES*

Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) chemokine or CCL5 is involved in immune cell transport to the inflammation site, promoting polarization towards an Th1 response [150]. Higher levels were associated with increased severity of lethargy, stereotypy and hyperactivity [149] in ASD patients.

#### *Eotaxin*

The CC chemokine eotaxin/CCL11 is known to bind to the receptor CCR3 on eosinophils and Th2-type lymphocytes [151]. Increased levels of Eotaxin were associated with increased severity of lethargy, stereotypy and hyperactivity in ASD subjects [149].

### **Final considerations**

Autistic Spectrum Disorder has a high prevalence and a growing incidence over the last few years. This has driven investments in public health and mobilized researchers and health professionals worldwide. There has been a significant progress in ASD research since the disorder was first described, but to date, its etiology remains unclear. An interesting hypothesis is that dysregulation of neuroimmune communication is involved in the onset of ASD. In this review, we summarized the main neuroimmune alterations found both in ASD subjects and in the VPA animal model of autism. Noticeably, several changes in the VPA model reflect the alterations found in patients with ASD (Figure 2). Animal models that present face and construct validity, such as the VPA model, can be an effective tool for the investigation of pathways and tissue alterations involved with the pathogenesis of ASD.

## Acknowledgments

This work was supported by development agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes) e Instituto Nacional de Ciência e Tecnologia em NeurolimunoModulação (INCT-NIM). The authors have no conflicts of interest.

## References

- 1 Leo Kanner: Autistic disturbance of affective contact. Pathology 1943 [cited 2018 Jan 27];2:217–250.
- 2 APA - American Psychiatric Association: DSM-5 Diagnostic Classification; in : Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, 2013. DOI: 10.1176/appi.books.9780890425596.x00DiagnosticClassification
- 3 Huerta M, Lord C: Diagnostic Evaluation of Autism Spectrum Disorders. Pediatr Clin North Am 2012;103–111.
- 4 Gadia CA, Tuchman R, Rotta NT: Autismo e doenças invasivas de desenvolvimento. J Pediatr 2004 [cited 2018 Jan 27];S83–S94.
- 5 Rapin I, Tuchman RF: Autism: Definition, Neurobiology, Screening, Diagnosis. Pediatr Clin North Am 2008;55:1129–1146.
- 6 Tonhajzerova I, Ondrejka I, Mestanik M, Mikolka P, Hrtanek I, Mestanikova A, et al.: Inflammatory Activity in Autism Spectrum Disorder; in : Advances in experimental medicine and biology. 2015, pp 93–98.
- 7 Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA:



1 Neuroglial activation and neuroinflammation in the brain of patients with  
2 autism. *Ann Neurol* 2005;57:67–81.

3 8 Autism Spectrum Disorders Working Group of The Psychiatric Genomics  
4 Consortium TASDWG of TPG: Meta-analysis of GWAS of over 16,000  
5 individuals with autism spectrum disorder highlights a novel locus at  
6 10q24.32 and a significant overlap with schizophrenia. *Mol Autism*  
7 2017;8:21.

8 9 Lintas C, Sacco R, Persico AM: Genome-wide expression studies in  
9 Autism spectrum disorder, Rett syndrome, and Down syndrome.  
10 *Neurobiol Dis* 2012;45:57–68.

11 10 Skafidas E, Testa R, Zantomio D, Chana G, Everall IP, Pantelis C:  
12 Predicting the diagnosis of autism spectrum disorder using gene pathway  
13 analysis. *Mol Psychiatry* 2014;19:504–510.

14 11 Christensen DL, Baio J, Braun KVN, Bilder D, Charles J, Constantino JN,  
15 et al.: Prevalence and Characteristics of Autism Spectrum Disorder  
16 Among Children Aged 8 Years — Autism and Developmental Disabilities  
17 Monitoring Network, 11 Sites, United States, 2012. *MMWR Surveill Summ*  
18 2016;65:1–23.

19 12 Smith V, Brown N: Prenatal valproate exposure and risk of autism  
20 spectrum disorders and childhood autism. *Arch Dis Child Educ Pract Ed*  
21 2014;99:198.

22 13 Rouillet FI, Lai JKY, Foster JA: In utero exposure to valproic acid and  
23 autism - A current review of clinical and animal studies. *Neurotoxicol*  
24 *Teratol* 2013;36:47–56.

- 1 14 Ranger P, Ellenbroek BA: Perinatal Influences of Valproate on Brain and  
2 Behaviour: An Animal Model for Autism; in : Current topics in behavioral  
3 neurosciences. 2015, pp 363–386.
- 4 15 Christianson AL, Chester N, Kromberg JGR: Fetal Valproate Syndrome:  
5 Clinical and Neuro-developmental Features in Two Sibling Pairs. Dev  
6 Med Child Neurol 1994;36:361–369.
- 7 16 Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, et  
8 al.: A clinical study of 57 children with fetal anticonvulsant syndromes. J  
9 Med Genet 2000 [cited 2018 Jan 29];37:489–497.
- 10 17 Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH: Fetal  
11 valproate syndrome and autism: additional evidence of an association.  
12 Dev Med Child Neurol 2001;43:202–206.
- 13 18 Williams PG, Hersh JH: A male with fetal valproate syndrome and autism.  
14 Dev Med Child Neurol 1997;39:632–634.
- 15 19 Bambini-Junior V, Rodrigues L, Behr GA, Moreira JCF, Riesgo R,  
16 Gottfried C: Animal model of autism induced by prenatal exposure to  
17 valproate: behavioral changes and liver parameters. Brain Res  
18 2011;1408:8–16.
- 19 20 Schneider T, Przewłocki R: Behavioral Alterations in Rats Prenatally  
20 Exposed to Valproic Acid: Animal Model of Autism.  
21 Neuropsychopharmacology 2005;30:80–89.
- 22 21 Schneider T, Roman A, Basta-Kaim A, Kubera M, Budziszewska B,  
23 Schneider K, et al.: Gender-specific behavioral and immunological  
24 alterations in an animal model of autism induced by prenatal exposure to

1 valproic acid. *Psychoneuroendocrinology* 2008;33:728–740.

2 22 Rouillet FI, Wollaston L, Decatanzaro D, Foster JA: Behavioral and  
3 molecular changes in the mouse in response to prenatal exposure to the  
4 anti-epileptic drug valproic acid. *Neuroscience* 2010;170:514–22.

5 23 Baronio D, Castro K, Gonchoroski T, de Melo GM, Nunes GDF, Bambini-  
6 Junior V, et al.: Effects of an H3R Antagonist on the Animal Model of  
7 Autism Induced by Prenatal Exposure to Valproic Acid. *PLoS One*  
8 2015;10:e0116363.

9 24 Favre MR, Barkat TR, Lamendola D, Khazen G, Markram H, Markram K:  
10 General developmental health in the VPA-rat model of autism. *Front*  
11 *Behav Neurosci* 2013;7:88.

12 25 Kataoka S, Takuma K, Hara Y, Maeda Y, Ago Y, Matsuda T: Autism-like  
13 behaviours with transient histone hyperacetylation in mice treated  
14 prenatally with valproic acid. *Int J Neuropsychopharmacol* 2013;16:91–  
15 103.

16 26 Zhubi A, Cook EH, Guidotti A, Grayson DR: Epigenetic mechanisms in  
17 autism spectrum disorder. ed 1 Elsevier Inc., 2014. DOI: 10.1016/B978-0-  
18 12-801311-3.00006-8

19 27 Uher R: Gene-environment interactions in severe mental illness. *Front*  
20 *psychiatry* 2014;5:48.

21 28 Misztak P, Pańczyszyn-Trzewik P, Sowa-Kućma M: Histone deacetylases  
22 (HDACs) as therapeutic target for depressive disorders. *Pharmacol*  
23 *Reports* 2018;70:398–408.

24 29 Koprinarova M, Schnekenburger M, Diederich M: Role of Histone

1        Acetylation in Cell Cycle Regulation. *Curr Top Med Chem* 2015;16:732–  
2        744.

3    30    Nadal S, Raj R, Mohammed S, Davis BG: Synthetic post-translational  
4        modification of histones. *Curr Opin Chem Biol* 2018;45:35–47.

5    31    Hu Y, Suliman BA: Roles of HDACs in the Responses of Innate Immune  
6        Cells and as Targets in Inflammatory Diseases. *Adv Exp Med Biol*  
7        2017;1024:91–110.

8    32    Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C,  
9        et al.: Activation of MHC class I, II, and CD40 gene expression by histone  
10       deacetylase inhibitors. *J Immunol* 2000 [cited 2018 Mar 18];165:7017–24.

11   33    Kroesen M, Gielen PR, Brok IC, Armandari I, Hoogerbrugge PM, Adema  
12       GJ: HDAC inhibitors and immunotherapy; a double edged sword?  
13       *Oncotarget* 2014;5:6558–6572.

14   34    Kawanai T, Ago Y, Watanabe R, Inoue A, Taruta A, Onaka Y, et al.:  
15       Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene  
16       Expression of Autism-Related Molecules and Delays Neuronal  
17       Maturation. *Neurochem Res* 2016;41:2574–2584.

18   35    Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria K, et al.:  
19       Altered proliferation and networks in neural cells derived from idiopathic  
20       autistic individuals. *Mol Psychiatry* 2017;22:820–835.

21   36    Kazlauskas N, Campolongo M, Lucchina L, Zappala C, Depino AM:  
22       Postnatal behavioral and inflammatory alterations in female pups  
23       prenatally exposed to valproic acid. *Psychoneuroendocrinology*  
24       2016;72:11–21.

- 1 37 Lee HJ, Dreyfus C, DiCicco-Bloom E: Valproic acid stimulates  
2 proliferation of glial precursors during cortical gliogenesis in developing  
3 rat. *Dev Neurobiol* 2016;76:780–798.
- 4 38 Perisic T, Zimmermann N, Kirmeier T, Asmus M, Tuorto F, Uhr M, et al.:  
5 Valproate and amitriptyline exert common and divergent influences on  
6 global and gene promoter-specific chromatin modifications in rat primary  
7 astrocytes. *Neuropsychopharmacology* 2010;35:792–805.
- 8 39 Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al.:  
9 Valproic acid defines a novel class of HDAC inhibitors inducing  
10 differentiation of transformed cells. *EMBO J* 2001;20:6969–78.
- 11 40 Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et  
12 al.: Structural and functional features of central nervous system lymphatic  
13 vessels. *Nature* 2015;523:337–41.
- 14 41 Louveau A, Harris TH, Kipnis J: Revisiting the Mechanisms of CNS  
15 Immune Privilege. *Trends Immunol* 2015;36:569–577.
- 16 42 Daneman R, Prat A: The blood-brain barrier. *Cold Spring Harb Perspect  
17 Biol* 2015;7:a020412.
- 18 43 Wang Y, Rattner A, Zhou Y, Williams J, Smallwood PM, Nathans J:  
19 Norrin/Frizzled4 Signaling in Retinal Vascular Development and Blood  
20 Brain Barrier Plasticity. *Cell* 2012;151:1332–1344.
- 21 44 Zhou Y, Nathans J: Gpr124 Controls CNS Angiogenesis and Blood-Brain  
22 Barrier Integrity by Promoting Ligand-Specific Canonical Wnt Signaling.  
23 *Dev Cell* 2014;31:248–256.
- 24 45 Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, et

1 al.: Canonical WNT signaling components in vascular development and  
2 barrier formation. *J Clin Invest* 2014;124:3825–3846.

3 46 Hagan N, Ben-Zvi A: The molecular, cellular, and morphological  
4 components of blood-brain barrier development during embryogenesis.  
5 *Semin Cell Dev Biol* 2015;38:7–15.

6 47 Zhao Z, Nelson AR, Betsholtz C, Zlokovic B V: Establishment and  
7 Dysfunction of the Blood-Brain Barrier. *Cell* 2015;163:1064–1078.

8 48 Daneman R, Zhou L, Kebede AA, Barres BA: Pericytes are required for  
9 blood–brain barrier integrity during embryogenesis. *Nature*  
10 2010;468:562–566.

11 49 Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al.:  
12 Pericytes Control Key Neurovascular Functions and Neuronal Phenotype  
13 in the Adult Brain and during Brain Aging. *Neuron* 2010;68:409–427.

14 50 Li Q, Barres BA: Microglia and macrophages in brain homeostasis and  
15 disease. *Nat Rev Immunol* 2017; DOI: 10.1038/nri.2017.125

16 51 Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely  
17 G, et al.: Identification of a unique TGF- $\beta$ –dependent molecular and  
18 functional signature in microglia. *Nat Neurosci* 2014;17:131–143.

19 52 Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres  
20 BA: Diverse Requirements for Microglial Survival, Specification, and  
21 Function Revealed by Defined-Medium Cultures. *Neuron* 2017;94:759–  
22 773.e8.

23 53 Kreutzberg GW: Microglia: a sensor for pathological events in the CNS.  
24 *Trends Neurosci* 1996 [cited 2018 Mar 23];19:312–8.

- 1    54    Raivich G, Banati R: Brain microglia and blood-derived macrophages:  
2            molecular profiles and functional roles in multiple sclerosis and animal  
3            models of autoimmune demyelinating disease. Brain Res Rev  
4            2004;46:261–281.
- 5    55    Nimmerjahn A, Kirchhoff F, Helmchen F: Resting Microglial Cells Are  
6            Highly Dynamic Surveillants of Brain Parenchyma in Vivo. Science (80- )  
7            2005;308:1314–1318.
- 8    56    Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J: Resting  
9            Microglia Directly Monitor the Functional State of Synapses In Vivo and  
10           Determine the Fate of Ischemic Terminals. J Neurosci 2009;29:3974–  
11           3980.
- 12   57    Olson JK, Miller SD: Microglia initiate central nervous system innate and  
13           adaptive immune responses through multiple TLRs. J Immunol 2004  
14           [cited 2018 Mar 23];173:3916–24.
- 15   58    Buttgereit A, Lelios I, Yu X, Vrohligs M, Krakoski NR, Gautier EL, et al.:  
16           Sall1 is a transcriptional regulator defining microglia identity and function.  
17           Nat Immunol 2016;17:1397–1406.
- 18   59    Parisi C, Napoli G, Pelegrin P, Volonté C: M1 and M2 Functional  
19           Imprinting of Primary Microglia: Role of P2X7 Activation and miR-125b.  
20           Mediators Inflamm 2016;2016:2989548.
- 21   60    Hanisch U-K, Prinz M, Angstwurm K, Hausler KG, Kann O, Kettenmann  
22           H, et al.: The protein tyrosine kinase inhibitor AG126 prevents the massive  
23           microglial cytokine induction by pneumococcal cell walls. Eur J Immunol  
24           2001 [cited 2018 Mar 23];31:2104–2115.

- 1 61 Häusler KG, Prinz M, Nolte C, Weber JR, Schumann RR, Kettenmann H,  
2 et al.: Interferon-gamma differentially modulates the release of cytokines  
3 and chemokines in lipopolysaccharide- and pneumococcal cell wall-  
4 stimulated mouse microglia and macrophages. *Eur J Neurosci* 2002 [cited  
5 2018 Mar 23];16:2113–22.
- 6 62 Škuljec J, Sun H, Pul R, Bénardais K, Ragancokova D, Moharreggh-  
7 Khiabani D, et al.: CCL5 induces a pro-inflammatory profile in microglia in  
8 vitro. *Cell Immunol* 2011;270:164–171.
- 9 63 Zarruk JG, Greenhalgh AD, David S: Microglia and macrophages differ in  
10 their inflammatory profile after permanent brain ischemia. *Exp Neurol*  
11 2018;301:120–132.
- 12 64 Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, et al.: Microglial and  
13 macrophage polarization—new prospects for brain repair. *Nat Rev Neurol*  
14 2015;11:56–64.
- 15 65 Hanisch U-K, Kettenmann H: Microglia: active sensor and versatile  
16 effector cells in the normal and pathologic brain. *Nat Neurosci*  
17 2007;10:1387–1394.
- 18 66 Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, et  
19 al.: Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial  
20 Activation States and Aspects of Alzheimer’s Disease Not Evident in  
21 Mouse Models. *Cell Rep* 2018;22:832–847.
- 22 67 Koyama R, Ikegaya Y: Microglia in the pathogenesis of autism spectrum  
23 disorders. *Neurosci Res* 2015;100:1–5.
- 24 68 Hansen D V., Hanson JE, Sheng M: Microglia in Alzheimer’s disease. *J*



1 Cell Biol 2018;217:459–472.

2 69 Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF,  
3 Lassmann H, et al.: Inflammatory Cortical Demyelination in Early Multiple  
4 Sclerosis. *N Engl J Med* 2011;365:2188–2197.

5 70 Antonietta Ajmone-Cat M, Mancini M, De Simone R, Cilli P, Minghetti L:  
6 Microglial polarization and plasticity: Evidence from organotypic  
7 hippocampal slice cultures. *Glia* 2013;61:1698–1711.

8 71 Serhan CN, Savill J: Resolution of inflammation: the beginning programs  
9 the end. *Nat Immunol* 2005;6:1191–1197.

10 72 Herz J, Filiano AJ, Smith A, Yogev N, Kipnis J: Myeloid Cells in the  
11 Central Nervous System. *Immun Rev* 2017; DOI:  
12 10.1016/j.immuni.2017.06.007

13 73 Serrats J, Schiltz JC, García-Bueno B, van Rooijen N, Reyes TM,  
14 Sawchenko PE: Dual Roles for Perivascular Macrophages in Immune-to-  
15 Brain Signaling. *Neuron* 2010;65:94–106.

16 74 Williams K, Alvarez X, Lackner AA: Central nervous system perivascular  
17 cells are immunoregulatory cells that connect the CNS with the peripheral  
18 immune system. *Glia* 2001 [cited 2018 Mar 23];36:156–64.

19 75 He H, Mack JJ, Güç E, Warren CM, Squadrito ML, Kilarski WW, et al.:  
20 Perivascular Macrophages Limit Permeability Highlights. *Arterioscler*  
21 *Thromb Vasc Biol* 2016;36:2203–2212.

22 76 Shechter R, London A, Schwartz M: Orchestrated leukocyte recruitment  
23 to immune-privileged sites: absolute barriers versus educational gates.  
24 *Nat Rev Immunol* 2013;13:206–218.

- 1 77 Quintana E, Fernández A, Velasco P, de Andrés B, Liste I, Sancho D, et  
2 al.: DNGR-1 + dendritic cells are located in meningeal membrane and  
3 choroid plexus of the noninjured brain. *Glia* 2015;63:2231–2248.
- 4 78 Meeker RB, Williams K, Killebrew DA, Hudson LC: Cell trafficking through  
5 the choroid plexus. *Cell Adh Migr* 2012;6:390–6.
- 6 79 Mendez-Gomez HR, Galera-Prat A, Meyers C, Chen W, Carrion-Vazquez  
7 M, Muzyczka N: Crossing the Blood-Cerebrospinal Fluid Barrier in the  
8 Mouse Choroid Plexus With an Engineered Receptor/Ligand System. *Mol*  
9 *Ther* 2015;23:S65.
- 10 80 Kierdorf K, Prinz M, Gomez Perdiguero E: Development and function of  
11 tissue resident macrophages in mice. *Semin Immunol* 2015;27:369–378.
- 12 81 Roth TL, Nayak D, Atanasijevic T, Koretsky AP, Latour LL, McGavern DB:  
13 Transcranial amelioration of inflammation and cell death after brain injury.  
14 *Nature* 2014;505:223–228.
- 15 82 Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD, et al.:  
16 CCR2+Ly-6Chi monocytes are crucial for the effector phase of  
17 autoimmunity in the central nervous system. *Brain* 2009;132:2487–2500.
- 18 83 Dong H, Zhang X, Qian Y: Mast cells and neuroinflammation. *Med Sci*  
19 *Monit Basic Res* 2014;20:200–6.
- 20 84 Prinz M, Priller J: The role of peripheral immune cells in the CNS in  
21 steady state and disease. *Nat Neurosci* 2017;20:136–144.
- 22 85 Nau R, Zettl U, Gerber J, Trostorf F, Michel U, Böttcher T, et al.:  
23 Granulocytes in the subarachnoid space of humans and rabbits with  
24 bacterial meningitis undergo apoptosis and are eliminated by

- 1       macrophages. *Acta Neuropathol* 1998;96:472–480.
- 2   86   McMenamin PG, Wealthall RJ, Deverall M, Cooper SJ, Griffin B:  
3       Macrophages and dendritic cells in the rat meninges and choroid plexus:  
4       three-dimensional localisation by environmental scanning electron  
5       microscopy and confocal microscopy. *Cell Tissue Res* 2003;313:259–  
6       269.
- 7   87   Chinnery HR, Ruitenberg MJ, McMenamin PG: Novel Characterization of  
8       Monocyte-Derived Cell Populations in the Meninges and Choroid Plexus  
9       and Their Rates of Replenishment in Bone Marrow Chimeric Mice. *J*  
10       *Neuropathol Exp Neurol* 2010;69:896–909.
- 11   88   Anandasabapathy N, Victora GD, Meredith M, Feder R, Dong B, Kluger  
12       C, et al.: Flt3L controls the development of radiosensitive dendritic cells in  
13       the meninges and choroid plexus of the steady-state mouse brain. *J Exp*  
14       *Med* 2011;208:1695–1705.
- 15   89   Prendergast CT, Anderton SM: Immune cell entry to central nervous  
16       system--current understanding and prospective therapeutic targets.  
17       *Endocr Metab Immune Disord Drug Targets* 2009 [cited 2018 Mar  
18       23];9:315–27.
- 19   90   Fabis MJ, Phares TW, Kean RB, Koprowski H, Hooper DC: Blood– brain  
20       barrier changes and cell invasion differ between therapeutic immune  
21       clearance of neurotrophic virus and CNS autoimmunity. *PNAS* 2008 [cited  
22       2018 Mar 23];Available from:  
23       <http://www.pnas.org/content/pnas/105/40/15511.full.pdf>
- 24   91   Arima Y, Kamimura D, Sabharwal L, Yamada M, Bando H, Ogura H, et

1 al.: Regulation of immune cell infiltration into the CNS by regional neural  
2 inputs explained by the gate theory. *Mediators Inflamm*  
3 2013;2013:898165.

4 92 Dendrou CA, Fugger L, Friese MA: Immunopathology of multiple  
5 sclerosis. *Nat Rev Immunol* 2015;15:545–558.

6 93 da Fonseca ACC, Matias D, Garcia C, Amaral R, Geraldo LH, Freitas C,  
7 et al.: The impact of microglial activation on blood-brain barrier in brain  
8 diseases. *Front Cell Neurosci* 2014;8:362.

9 94 Phares TW, Kean RB, Mikheeva T, Hooper DC: Regional Differences in  
10 Blood-Brain Barrier Permeability Changes and Inflammation in the  
11 Apathogenic Clearance of Virus from the Central Nervous System. *J*  
12 *Immunol* 2006;114:1761–5.

13 95 Bilbo SD, Block CL, Bolton JL, Hanamsagar R, Tran PK: Beyond infection  
14 - Maternal immune activation by environmental factors, microglial  
15 development, and relevance for autism spectrum disorders. *Exp Neurol*  
16 2018;299:241–251.

17 96 Ashwood P, Wills S, Van de Water J: The immune response in autism: a  
18 new frontier for autism research. *J Leukoc Biol* 2006;80:1–15.

19 97 Turner MD, Nedjai B, Hurst T, Pennington DJ: Cytokines and  
20 chemokines: At the crossroads of cell signalling and inflammatory  
21 disease. *Biochim Biophys Acta* 2014;1843:2563–2582.

22 98 Masi A, Glozier N, Dale R, Guastella AJ: The Immune System, Cytokines,  
23 and Biomarkers in Autism Spectrum Disorder. *Neurosci Bull*  
24 2017;33:194–204.

- 1 99 Ramesh G, MacLean AG, Philipp MT: Cytokines and chemokines at the  
2 crossroads of neuroinflammation, neurodegeneration, and neuropathic  
3 pain. *Mediators Inflamm* 2013;2013:480739.
- 4 100 Biber K, Vinet J, Boddeke HWGM: Neuron-microglia signaling:  
5 Chemokines as versatile messengers. *J Neuroimmunol* 2008;198:69–74.
- 6 101 Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Mélik  
7 Parsadaniantz S: Current status of chemokines in the adult CNS. *Prog*  
8 *Neurobiol* 2013;104:67–92.
- 9 102 Charles A Janeway J, Travers P, Walport M, Shlomchik MJ:  
10 *Immunobiology: The Immune System in Health and Disease*. Garland  
11 Science, 2001, [cited 2018 Mar 18]. Available from:  
12 <https://www.ncbi.nlm.nih.gov/books/NBK27092/>
- 13 103 Metz DP, Bottomly K: Function and regulation of memory CD4 T cells.  
14 *Immunol Res* 1999;19:127–141.
- 15 104 Amedei A, Prisco D, D'Elia M: Multiple Sclerosis: The Role of Cytokines  
16 in Pathogenesis and in Therapies. *Int J Mol Sci* 2012;13:13438–13460.
- 17 105 Vijayakumar NT, Judy M V.: Autism spectrum disorders: Integration of the  
18 genome, transcriptome and the environment. *J Neurol Sci* 2016; DOI:  
19 10.1016/j.jns.2016.03.026
- 20 106 Ertuğ M, Giralt M, Esposito FL, Fernandez-Gayol O, Hidalgo J: Astrocytic  
21 IL-6 mediates locomotor activity, exploration, anxiety, learning and social  
22 behavior. *Horm Behav* 2015;73:64–74.
- 23 107 Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, et  
24 al.: Brain IL-6 elevation causes neuronal circuitry imbalances and

1           mediates autism-like behaviors. *Biochim Biophys Acta - Mol Basis Dis*  
2           2012;1822:831–842.

3   108   Bluthé RM, Michaud B, Poli V, Dantzer R: Role of IL-6 in cytokine-induced  
4           sickness behavior: a study with IL-6 deficient mice. *Physiol Behav* 2000  
5           [cited 2018 Mar 19];70:367–73.

6   109   Lucchina L, Depino AM: Altered Peripheral and Central Inflammatory  
7           Responses in a Mouse Model of Autism. *Autism Res* 2013;7:273–289.

8   110   Gottfried C, Bambini-Junior V, Francis F, Riesgo R, Savino W: The  
9           Impact of Neuroimmune Alterations in Autism Spectrum Disorder. *Front*  
10          *psychiatry* 2015;6:121.

11   111   Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S:  
12          Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and  
13          Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.  
14          *Mediators Inflamm* 2017;2017:1852517.

15   112   Dinarello CA: Immunological and Inflammatory Functions of the  
16          Interleukin-1 Family. *Annu Rev Immunol* 2009;27:519–550.

17   113   Gray SM, Bloch MH: Systematic review of proinflammatory cytokines in  
18          obsessive-compulsive disorder. *Curr Psychiatry Rep* 2012;14:220–8.

19   114   Manzardo AM, Henkhaus R, Dhillon S, Butler MG: Plasma cytokine levels  
20          in children with autistic disorder and unrelated siblings. *Int J Dev Neurosci*  
21          2012;30:121–127.

22   115   Suzuki K, Matsuzaki H, Iwata K, Kamenno Y, Shimmura C, Kawai S, et al.:  
23          Plasma cytokine profiles in subjects with high-functioning autism  
24          spectrum disorders. *PLoS One* 2011;6:1–6.

- 1 116 Emanuele E, Orsi P, Boso M, Broglia D, Brondino N, Barale F, et al.: Low-  
2 grade endotoxemia in patients with severe autism. *Neurosci Lett*  
3 2010;471:162–165.
- 4 117 Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, et al.:  
5 Altered cytokine and BDNF levels in autism spectrum disorder. *Neurotox*  
6 *Res* 2013;24:491–501.
- 7 118 Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential  
8 monocyte responses to TLR ligands in children with autism spectrum  
9 disorders. *Brain Behav Immun* 2010;24:64–71.
- 10 119 Jyonouchi H, Sun S, Le H: Proinflammatory and regulatory cytokine  
11 production associated with innate and adaptive immune responses in  
12 children with autism spectrum disorders and developmental regression. *J*  
13 *Neuroimmunol* 2001;120:170–179.
- 14 120 Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de  
15 Water J: Elevated plasma cytokines in autism spectrum disorders provide  
16 evidence of immune dysfunction and are associated with impaired  
17 behavioral outcome. *Brain Behav Immun* 2011;25:40–45.
- 18 121 Abdallah MW, Larsen N, Mortensen EL, Atladóttir HÓ, Nørgaard-  
19 Pedersen B, Bonefeld-Jørgensen EC, et al.: Neonatal levels of cytokines  
20 and risk of autism spectrum disorders: An exploratory register-based  
21 historic birth cohort study utilizing the Danish Newborn Screening  
22 Biobank. *J Neuroimmunol* 2012;252:75–82.
- 23 122 Theije CGM, Wu J, Koelink PJ, Korte-Bouws GAH, Borre Y, Kas MJH, et  
24 al.: Autistic-like behavioural and neurochemical changes in a mouse

- 1 model of food allergy. Behav Brain Res 2014;261:265–274.
- 2 123 Wu H, Wang X, Gao J, Liang S, Hao Y, Sun C, et al.: Fingolimod  
3 (FTY720) attenuates social deficits, learning and memory impairments,  
4 neuronal loss and neuroinflammation in the rat model of autism. Life Sci  
5 2017;173:43–54.
- 6 124 Hegazy HG, Ali EHA, Elgoly AHM: Interplay between pro-inflammatory  
7 cytokines and brain oxidative stress biomarkers: Evidence of parallels  
8 between butyl paraben intoxication and the valproic acid brain  
9 physiopathology in autism rat model. Cytokine 2015;71:173–180.
- 10 125 Kelly E, Won A, Refaeli Y, Van Parijs L: IL-2 and related cytokines can  
11 promote T cell survival by activating AKT. J Immunol 2002 [cited 2018  
12 Mar 20];168:597–603.
- 13 126 Malek TR: The main function of IL-2 is to promote the development of T  
14 regulatory cells. J Leukoc Biol 2003;74:961–965.
- 15 127 Fukuda T, Fukushima Y, Numao T, Ando N, Arima M, Nakajima H, et al.:  
16 Role of interleukin-4 and vascular cell adhesion molecule-1 in selective  
17 eosinophil migration into the airways in allergic asthma. Am J Respir Cell  
18 Mol Biol 1996;14:84–94.
- 19 128 Abdallah MW, Larsen N, Grove J, Rgaard-pedersen BNØ, Thorsen P,  
20 Mortensen EL, et al.: Amniotic fluid inflammatory cytokines : Potential  
21 markers of immunologic dysfunction in autism spectrum disorders. World  
22 J Biol Psychiatry 2013;528–538.
- 23 129 Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW: Th2  
24 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic



1 disease. *Respir Res* 2001;2:71–9.

2 130 Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH: Maternal Immune  
3 Activation Alters Fetal Brain Development through Interleukin-6. *J*  
4 *Neurosci* 2007 [cited 2018 May 3];Available from:  
5 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387067/pdf/nihms42804.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387067/pdf/nihms42804.pdf)  
6 pdf

7 131 Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, et al.: IL-6 is  
8 increased in the cerebellum of autistic brain and alters neural cell  
9 adhesion, migration and synaptic formation. *J Neuroinflammation*  
10 2011;8:1–10.

11 132 Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al.: Elevated  
12 immune response in the brain of autistic patients. *J Neuroimmunol*  
13 2009;207:111–116.

14 133 Bickel M: The role of interleukin-8 in inflammation and mechanisms of  
15 regulation. *J Periodontol* 1993 [cited 2018 Mar 20];64:456–60.

16 134 Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA:  
17 Neuroglial activation and neuroinflammation in the brain of patients with  
18 autism. *Ann Neurol* 2005;57:67–81.

19 135 Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, et al.: Regulation of IL-10  
20 and IL-12 production and function in macrophages and dendritic cells.  
21 *F1000Research* 2015;4. DOI: 10.12688/f1000research.7010.1

22 136 Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A: The IL-12 family of  
23 cytokines in infection, inflammation and autoimmune disorders. *Inflamm*  
24 *Allergy Drug Targets* 2009 [cited 2018 Mar 20];8:40–52.

- 1 137 Bao K, Reinhardt RL: The differential expression of IL-4 and IL-13 and its  
2 impact on type-2 immunity. *Cytokine* 2015;75:25–37.
- 3 138 Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T: The Role of IL-17 and  
4 Related Cytokines in Inflammatory Autoimmune Diseases. *Mediators*  
5 *Inflamm* 2017;2017:1–11.
- 6 139 ZHONG F, CUI D, TAO H, DU H, XING C: IL-17A-producing T cells and  
7 associated cytokines are involved in the progression of gastric cancer.  
8 *Oncol Rep* 2015;34:2365–2374.
- 9 140 Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim S V, et al.: The maternal  
10 interleukin-17a pathway in mice promotes autism-like phenotypes in  
11 offspring. *Science* 2016;351:933–9.
- 12 141 AL-Ayadhi LY, Mostafa GA: Elevated serum levels of interleukin-17A in  
13 children with autism. *J Neuroinflammation* 2012;9:595.
- 14 142 Toussiot E: The IL23/Th17 pathway as a therapeutic target in chronic  
15 inflammatory diseases. *Inflamm Allergy Drug Targets* 2012 [cited 2018  
16 Mar 20];11:159–68.
- 17 143 Fischer K, Przepiera-Będzak H, Sawicki M, Walecka A, Brzosko I,  
18 Brzosko M: Serum Interleukin-23 in Polish Patients with Systemic Lupus  
19 Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral  
20 Vascular Disease. *Mediators Inflamm* 2017; DOI: 10.1155/2017/9401432
- 21 144 Ziblat A, Nuñez SY, Raffo Iraolagoitia XL, Spallanzani RG, Torres NI,  
22 Sierra JM, et al.: Interleukin (IL)-23 Stimulates IFN- $\gamma$  Secretion by  
23 CD56bright Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells  
24 Activation. *Front Immunol* 2018;8:1959.

- 1 145 Jyonouchi H, Sun S, Itokazu N: Innate immunity associated with  
2 inflammatory responses and cytokine production against common dietary  
3 proteins in patients with autism spectrum disorder. *Neuropsychobiology*  
4 2002;46:76–84.
- 5 146 Mah AY, Cooper MA: Metabolic Regulation of Natural Killer Cell IFN- $\gamma$   
6 Production. *Crit Rev Immunol* 2016;36:131–147.
- 7 147 Tostes MHFS, Teixeira HC, Gattaz WF, Brandão MAF, Raposo NRB:  
8 Altered neurotrophin, neuropeptide, cytokines and nitric oxide levels in  
9 autism. *Pharmacopsychiatry* 2012;45:241–243.
- 10 148 Gutiérrez IL, González-Prieto M, García-Bueno B, Caso JR, Feinstein DL,  
11 Madrigal JLM: CCL2 Induces the Production of  $\beta$ 2 Adrenergic Receptors  
12 and Modifies Astrocytic Responses to Noradrenaline. *Mol Neurobiol*  
13 2018;1–14.
- 14 149 Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de  
15 Water J: Associations of impaired behaviors with elevated plasma  
16 chemokines in autism spectrum disorders. *J Neuroimmunol* 2011; DOI:  
17 10.1016/j.jneuroim.2010.10.025
- 18 150 Fichna M, Żurawek M, Budny B, Komarowska H, Niechciał E, Fichna P, et  
19 al.: Elevated serum RANTES chemokine in autoimmune Addison's  
20 disease. *Polish Arch Intern Med* 2018; DOI: 10.20452/pamw.4221
- 21 151 Cheng SS, Lukacs NW, Kunkel SL: Eotaxin/CCL11 suppresses IL-  
22 8/CXCL8 secretion from human dermal microvascular endothelial cells. *J*  
23 *Immunol* 2002 [cited 2018 Mar 20];168:2887–94.
- 24 152 Ahmad SF, Zoheir KMA, Ansari MA, Nadeem A, Bakheet SA, AL-Ayadhi

1 LY, et al.: Dysregulation of Th1, Th2, Th17, and T regulatory cell-related  
2 transcription factor signaling in children with autism. *Mol Neurobiol*  
3 2017;54:4390–4400.

4 153 Ashwood P, Anthony A, Torrente F, Wakefield AJ: Spontaneous mucosal  
5 lymphocyte cytokine profiles in children with autism and gastrointestinal  
6 symptoms: Mucosal immune activation and reduced counter regulatory  
7 interleukin-10. *J Clin Immunol* 2004;24:664–673.

8 154 Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential  
9 monocyte responses to TLR ligands in children with autism spectrum  
10 disorders. *Brain Behav Immun* 2010;24:64–71.

11

**Table 1.** Main cytokines with altered levels in autism subjects

DSM	Severity	Described comorbidities	Age (years)	Source	Outcome	Analysis method	Reference
ASD	ND	ND	neonatal	amniotic fluid	↑ MCP-1, IL-4, IL-10, TNF- $\alpha$ and TNF- $\beta$	Flow cytometry	[128]
ASD	ND	ND	neonatal	n-DBSS	↓ IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, GM-CSF, IFN- $\gamma$ ↑ sIL-6R $\alpha$ , IL-8	Flow cytometry	[121]
ASD (DSM-IV)	Mild, moderate and Severe	ND	2-21	Serum	↑ IL-1, IL-6, IL-12, IL-23, TNF- $\alpha$	ELISA	[117]
ASD (DSM-5)	ND	ND	3-11	PBMCs	↓ CD4+, FOXP3+, T cells ↓ mRNA and protein expression FoxP3 ↑ Tbet, ↑ STAT3, ↑ GATA3	Flow cytometry, PCR and Western Blotting	[152]
ASD (DSM-5)	ND	ND	3-11	PBMCs	↑ ROR- $\gamma$ t in CD4	PCR and Western Blotting	[152]
ASD (DSM-IIIIR/DSM-IV)	ND	GI issues	2-16	Duodenal Lamina Propria	↑ CD3+/TNF $\alpha$ + ↓ CD3+/IL-10+	Flow cytometry	[153]
ASD (DSM-IIIIR/DSM-IV)	ND	GI issues	2-16	Epithelium	↑ CD3+/TNF $\alpha$ + ↓ CD3+/IL-10+	Flow cytometry	[153]
ASD (DSM-IV)	ND	ND	1-17	PBMCs	↑ TNF- $\alpha$	ELISA	[145]
ASD (DSM-IV)	ND	GI issues	4-15	PBMCs	↑ TNF- $\alpha$ , IFN- $\gamma$ ↓ IL-10	Flow cytometry	[96]
ASD (DSM-IV)	Severe (nonverbal adult patients)	ND	18-44	Serum	↑ IL-1 $\beta$ , IL-6	ELISA	[116]

ASD (DSM-IV)	ND	ND	2.9-4.3	PBMCs	↑ IL-1β, IL-6, IL-8, IL-12 p40	Multiplexing bead immunoassays	[120]
ASD (DSM-IV)	ND	ND	2-14	PBMCs	↑ TNF-α, TNFRI, TNFRII, IL-6, IL-1β	ELISA	[119]
ASD (DSM-IV)	ND	ND	2.2-5	PBMCs	↑ IL-1β, IL-6, TNF-α	Flow cytometry	[154]
ASD (DSM-IV)	ND	ND	5-44	<i>post mortem</i> brain tissue	↑ IL-6, IL10, TGFβ1 (anterior cingulate gyrus)	Human cytokine array kits	[7]
ASD (DSM-IV)	ND	ND	5-44	CSF	↑ IFNγ, TGFβ2, IL-8, MCP1	Human cytokine array kits	[7]
ASD (DSM-IV)	ND	ND	4-37	<i>post mortem</i> brain tissue	↑ IFNγ, IL-6, IL-8, TNF-α (frontal cortex)	Multiplex Bead Immunoassays	[132]
ASD (DSM-IV)	ND	ND	4-14	<i>post mortem</i> brain tissue	↑ IL-6 (cerebellum)	Immunohistochemistry	[131]
ASD (DSM-IV)	ND	ND	7-15	Plasma	↑ IL-1β, IL-1RA, IL-5, IL-8, IL-12 (p70), IL-13, IL-17	ELISA	[115]
ASD (DSM-IV)	ND	ND	3-4.5	Plasma	↑ MCP-1, RANTES, Eotaxin	Multiplexing bead immunoassays	[149]
ASD (DSM-IV)	ND	ND	4.7-10.1	Plasma	↑ IFN-γ	ELISA	[147]
ASD (DSM-IV)	Mild to moderate and Severe	ND	6-11	Serum	↑ IL-17A (proportional increase to severity of autism)	ELISA	[141]
ASD (DSM-IV)	ND	ND	5-10	Plasma	↑ IL-1a ↓ IL-6, G-CSF, EGF	ELISA	[114]

**DSM:** Diagnostic and Statistical Manual of Mental Disorders; **CSF:** cerebrospinal fluid; **ELISA:** enzyme-linked immunosorbent assay; **IFN:** interferon; **IL:** interleukin; **ND:** not described; **n-DBSS:** neonatal dried blood samples; **PBMC:** peripheral blood mononuclear cells; **PCR:** polymerase chain reaction; **TNF:** tumor necrosis factor.

**Table 2.** Main cytokines with altered levels in the valproic acid animal model of autism

Animal	Dosage	Embryonic day	Administration via	Source	Age	Outcome	Analysis method	References
BALB/c	600 mg/Kg	E11	Subcutaneous	Dorsal hippocampus	P28	↑ IL-1β	PCR	[122]
BALB/c	400 mg/Kg and 600 mg/Kg	E12.5	Subcutaneous	Spleen	8-10 weeks	Only VPA did not onset inflammatory response, but showed exacerbated response to a LPS challenge: ↑ IL-1β, IL-6 and TNF-α expression	PCR	[109]
BALB/c	400 mg/Kg and 600 mg/Kg	E12.5	Subcutaneous	Hippocampus/ Cerebellum	8-10 weeks	↑ IL-6 and TNF-α expression in VPA animals exposed to a LPS challenge	PCR	[109]
Wistar	600 mg/Kg	E12.5	Intraperitoneal	Hippocampus	P40	↑ IL-6, ↑ IL-1β	ELISA	[123]
Wistar	800 mg/Kg	E12.5	Gavage	Whole brain	P21	↑ IL-1β, IL-6, TNF-α	ELISA	[124]


**IL:** interleukin; **PCR:** polymerase chain reaction.

## Legend of figures


**Figure 1. Th1, Th2, Th17 commitment lineage from naïve CD4+ T cells.** The main functions of each immune response and the signature cytokine are highlighted in the boxes. APC: antigen-presenting cell; NK: natural killer cell; T-bet: T box expressed in T cells; GATA: GATA-binding protein; ROR: Retinoid-related orphan receptor; IL: Interleukin; IFN: Interferon; TGF: Transforming growth factor.

**Figure 2. Main results of cytokines altered both in ASD subjects and in VPA animal model.** At the interface of the columns and rows are shown the common findings both to humans and to animal model in different biological sources. The references are already cited in Table 1.





**Figure 1. Th1, Th2, Th17 commitment lineage from naïve CD4+ T cells.**



**Figure 2. Main results of cytokines altered both in ASD subjects and in VPA animal model.**